Arbutus Biopharma Corp (ABUS) Presyo ng Stock at Balita

HomeABUS • NASDAQ

Arbutus Biopharma Corp

$4.26

Mar 16, 8:20:34 AM GMT-4 · USD · NASDAQ · Disclaimer

StockSegurong nakalista sa USMay headquarter sa US

Nakaraang pagsara

$4.26

Sakop ng taon

$2.71 - $5.10

Market cap

819.30M USD

Average na Volume

2.67M

P/E ratio

Dividend yield

Primary exchange

NASDAQ

Mga balita tungkol sa merkado

GlobeNewswire

19 minuto ang nakalipas

JFB (NASDAQ: JFB) Announces XTEND and Rayonix Execute

JFB

0.00%

Lexington Herald Leader

41 minuto ang nakalipas

New to The Street Broadcasts Episode Featuring FreeCast (NASDAQ:CAST), KLED.AI, PetVivo (OTCQB:PETV), EmpowerLit, and BlackBarn NYC on Bloomberg Television - March 21 at 6:30 PM EST

45 minuto ang nakalipas

Cycurion (Nasdaq: CYCU) Announces Definitive Agreement to Acquire Federal Cybersecurity Firm and Reports Record Contracted Backlog Exceeding $150 Million

54 minuto ang nakalipas

Trump has 15 days to end the Iran war or markets face a brutal April repricing — from oil to the S&P 500

Severe oil shock could drag S&P 500 down to 5,400, Goldman warns

.INX

0.00%

Yahoo Finance

49 minuto ang nakalipas

CareCloud to Ring Nasdaq Closing Bell on May 19, 2026 and Host Analyst Day at Nasdaq MarketSite in New York City

CCLD

7.90%

Tungkol

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection. It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia

CEO

William H. Collier

Itinatag

2007

Headquarters

Warminster Township, Pennsylvania
Estados Unidos

Website

arbutusbio.com

Mga Empleyado